Alternative Treatment to Multisystem Inflammatory Syndrome in Children Kawasaki Phenotype
Article Sidebar
Main Article Content
Abstract
During the COVID 19 pandemic multisystem inflammatory syndrome in children (MIS-C) has been reported quite often in different countries. This case report is about a 4-year-old child who presented with fever , maculopapular rash, abdominal pain for 3 days with exposure to COVID 19 in the past. Child was started on ceftriaxone and doxycycline. Covid antibody IgG detected to be positive. Considering age, mucocutaneous involvement without shock, child was diagnosed as MIS-C kawasaki phenotype without shock. Child was treated with intravenous methylprednisolone. Follow up showed no coronary dilatation. In a resource limiting setting, it is reasonable to consider steroids as a firstline.
Article Details
References
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DS, Du B. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine. 2020 Apr 30;382(18):1708-20.Med 2020;382:1708.https://doi.org/10.1056/NEJMoa2002032
Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine. 2020 May 1;8(5):475-81.https://doi.org/10.3389/fped.2020.594127
Fouriki A, Fougère Y, De Camaret C, Blanchard Rohner G, Grazioli S, Wagner N, Relly C, Pachlopnik Schmid J, Trück J, Kottanatu L, Perez E. Case report: case series of children with multisystem inflammatory syndrome following SARS-CoV-2 infection in Switzerland. Frontiers in Pediatrics. 2021 Jan 5;8:863.https://doi.org/10.3389/fped.2020.594127
Son M, Friedman K, Kaplan SL, Sundel R, Randolph AG. COVID-19: multisystem inflammatory syndrome in children (MIS-C) management and outcome. Up to Date. 2021.
Godfred-Cato S, Bryant B, Leung J, Oster ME, Conklin L, Abrams J, Roguski K, Wallace B, Prezzato E, Koumans EH, Lee EH. COVID-19–associated multisystem inflammatory syndrome in children—United States, March–July 2020. Morbidity and Mortality Weekly Report. 2020 Aug 14;69(32):1074.http://dx.doi.org/10.15585/mmwr.mm6932e2
McArdle AJ, Vito O, Patel H, Seaby EG, Shah P, Wilson C, Broderick C, Nijman R, Tremoulet AH, Munblit D, Ulloa-Gutierrez R. Treatment of multisystem inflammatory syndrome in children. New England Journal of Medicine. 2021 Jul 1;385(1):11-22.https://doi.org/10.1056/NEJMoa2102968
Crosby L, Balasubramanian S, Ramanan AV. Steroids or intravenous immunoglobulin as first line in MIS-C in LMICs. The Lancet Rheumatology. 2021 Sep 1;3(9):e615-6.https://doi.org/10.1016/S2665-9913(21)00223-X
Licciardi F, Baldini L, Dellepiane M, Covizzi C, Mogni R, Pruccoli G, Orsi C, Rabbone I, Parodi E, Mignone F, Montin D. MIS-C Treatment: Is IVIG Always Necessary?. Frontiers in Pediatrics. 2021;9.https://doi.org/10.3389/fped.2021.753123